Platelet-derived extracellular vesicles to target plaque inflammation for effective anti-atherosclerotic therapy

Reshaping the Inflammatory Environment in Rheumatoid Arthritis Joints by Targeting Delivery of Berberine with Platelet‐Derived Extracellular Vesicles

“…The preparation of PEVs was based on the protocol previously reported by our laboratory. [18,19] The size and morphology of these vesicles were uniform as revealed by transmission electron microscopy (Figure 1b). The average hydrodynamic size of PEVs was about 140 nm as measured by dynamic light Scattering (DLS) (Figure 1c).…”

“…In our previous study, we have demonstrated that PEVs exhibit great targeting capacity to various inflammatory site. [18,19] We subsequently investigated the biodistribution of PEVs in mice with RA. The RA model was successfully established according to the literature [26] (Figure S4, Supporting Information).…”

“…[15][16][17] We have previously found that platelet-derived extracellular vesicles (PEVs) which are naturally occurring nanoparticles released by platelets, can selectively target different sites of various inflammation, which is a kind of universal tool for inflammation diagnosis and treatment. [18,19] Berberine (BBR) is an alkaloid widely studied for the treatment of RA due to their anti-inflammation effect. [20,21] In preclinical studies, BBR has been proven by inhibiting inflammatory proliferation of macrophages and suppressing dendritic cells activation to inhibit inflammation of synovial joints, and by participating in a variety of inflammatory signaling cascades and apoptosis-mediated pathway to ameliorate RA.…”

Integrative biology of extracellular vesicles in diabetes mellitus and diabetic complications

“…Another important clinical application of EVs from different origins is in treating diabetic complications, such as DN 463 - 466 , DR 467 - 471 , diabetic erectile dysfunction 472 - 475 , diabetic foot 476 - 490 , diabetic cardiomyopathy 217 , atherosclerosis 491 - 500 , and diabetic peripheral neuropathy 429 (Figure 7 ). Currently, the therapeutic roles of EVs in treating diabetic complications are mostly attributed to the delivery of ncRNAs, especially miRNAs.…”

Characterization and Therapeutic Use of Extracellular Vesicles Derived from Platelets

“…As a kind of immune cell, PL-EVs has an inherent affinity for inflammation sites, including atherosclerotic plaque sites, so they could be used for the delivery of anti-inflammatory agents. Recently, Ma et al [ 138 ] showed that nano-sized MCC950-loaded PL-EVs could selectively bind multiple cell types such as macrophages and epithelial cells and have an efficient anti-inflammatory effect on atherosclerotic plaque after intravenous administration in an ApoE-KO mice model of atherosclerosis.…”